Method for reducing emotional lability
Patent 5206248 Issued on April 27, 1993. Estimated Expiration Date: 
March 27, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 27, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorApplicationNo. 859105 filed on 03/27/1992US Classes:514/289, Two of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.)514/282, One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.)514/305Quinuclidines (including unsaturation)ExaminersPrimary: Waddell, Frederick E.Assistant: Jordan, Kimberly Attorney, Agent or FirmInternational ClassA61K 031/44AbstractThis invention discloses that certain types of non-addictive opioid drugs such as dextromethorphan (which is widely used in cough syrups) provide a highly effective means of treating the feelings and symptoms of emotional lability in at least some patients suffering from neurologic impairment, without sedating, tranquilizing, or otherwise significantly interfering with consciousness or alertness in the patient. In several patients tested to date who were suffering from amyotrophic lateral sclerosis (ALS), dextromethorphan, administered orally, was remarkably effective and became quite obvious to the patients even though it was being tested for an entirely different purpose. Its effectiveness is enhanced by co-administration of a second drug such as quinidine which reduces the degradation of dextromethorphan by oxidative enzymes and which therefore increases dextromethorphan concentrations in the blood.Other References
| |
